Release date: 2016-02-17
Lung cancer is the second most common cancer in the human body except skin cancer, and it is the cancer that has the highest mortality rate so far. Since 2008 , lung cancer has replaced liver cancer as the number one cancer killer in China. In the past three decades, the number of Chinese lung cancer deaths has increased by 464.85% . Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer .
Most doctors believe that prevention and early monitoring of lung cancer is the best way to fight lung cancer. Previously , doctors would recommend three different types of lung cancer tests : imaging , sputum cytology, and tissue biopsy. However , these diagnostic methods are not only cumbersome but also expensive. These diagnostic methods are effective only when suspicious signs are found in the body and the probability of developing cancer is reasonable. Most patients realize that it is too late to get cancer. Therefore , the survival rate of lung cancer patients has been very low in the past few decades.
Since 2011 , the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCC) have recommended advanced detection of the epidermal growth factor receptor (EGFR) method for the diagnosis of non-small cell lung cancer . Briefly , EGFR therapy is targeted for the treatment of lung cancer by EGFR- tyrosine kinase inhibitors such as geftinib (gefitinib) or erlotiniv (erlotinib). Although this greatly improves the survival rate , it also requires a high level of resources , a large number of professionals and time.
Chinese scientists master the core technology of non-invasive gene precision diagnosis
In this context, Dr. Liao Wei, a researcher from the University of California, Los Angeles, UCLA , began his entrepreneurial journey. He founded a genetic diagnosis company called Yihuo Bio , and hired Professor UCLA . David King (David Wong) chief scientist, the goal is to develop more accurate, more convenient, more economical super genetic testing tool.
On February 12, 2016, Dr. Liao Wei and Professor David Wang introduced the epoch-making technology EFIRM of the living organisms to scientists and media around the world at the American Association for the Advancement of Science AAAS 2016 Annual Meeting and Global Science Conference. Immediately triggered the scrutiny of hundreds of media around the world, the arterial network had previously entered an exclusive English interview with Dr. Liao Wei (the English report was attached to the Chinese content).
EFIRM is easy to use but powerful, it can accurately diagnose the most common lung cancer subtypes, and judge non-small cell lung cancer through a simple body fluid analysis. This process is called "body fluid biopsy", which avoids the damage caused by traditional biopsy. Therefore, the advantages of the new lung cancer diagnosis method are self-evident. In addition to being non-invasive, clinical tests have shown that it can achieve high detection accuracy of over 99%. It has also proven to be cheap and efficient. Liao Wei told the arterial network that EFIRM can diagnose the most common lung cancer subtypes in less than 30 minutes.
The basic principle of EFIRM is to use ultra-high sensitivity electrochemical detection method to specifically capture free tumor gene fragments, and directly read the gene mutation information in body fluid without sample processing and PCR amplification, so it is called electric field induced release. And measurement (EFIRM) . Products developed on the basis of this technology are called eLB . Liao Wei said that the core technology of EFIRM is completely in the hands of Chinese. EFIRM instruments and kits are completely developed by Easy Bio.
The company is headquartered in the United States and is conducting clinical trials and construction production sites in China. It is expected that by the summer of 2016 , the factory will be able to produce subversive tumor genetic testing equipment and lung cancer detection reagents in large quantities. In June 2016, the company plans to release the first generation of official products at the ASCO conference in Chicago, USA and officially entered the market.
Hope to benefit more people
Liao Wei graduated from the Chemistry College of Peking University and is also a successful man with a happy marriage. Before returning home, he was a researcher at the UCLA School of Medicine. As he said , he has a clear vision of the future of the company. He said sincerely: " The more people who can benefit from this new technology, the better. " " We have our own patents , but we don't mind sharing with people with the same vision, we want to help as many people as possible. " Tell the arterial network. The company plans to produce first in China and then quickly spread to the entire domestic market. After all, China has become the second largest economy in the world. In 2017 , the company plans to promote its products to other parts of the world.
The product is of extraordinary significance and is in line with Dr. Liao's vision. For example , he wants to make this platform an "Apple store" for the next generation of genetic mutation detection. This platform is open to developers and he hopes to detect any disease through genetic mutation in the near future. A large number of test application kits will appear on this platform, each of which can detect a genetic mutation in a disease, and the kit is disposable. Its expected price is one tenth of the current diagnostic method price.
This product has three distinct advantages over its potential competitors. First, other diagnostic methods are based on polymerase chain reaction (PCR) . It has obvious weaknesses - it requires tissue biopsy and is therefore considered an invasive diagnostic method. In addition , in order to detect gene mutations, PCR requires pre-amplification of target DNA or RNA sequences. Second , its accuracy is lower than eLB . The coincidence rate of PCR humoral biopsy and tissue biopsy is less than 70% , and eLB can achieve a compliance rate of more than 99% by detecting only body fluid without PCR amplification. Moreover , this PCR diagnostic method is expensive, costing about $ 450 in China and is particularly time consuming , about 10-14 days. In comparison, EFIRM technology is expected to cost around $ 50 and no more than 30 minutes.
Liao Wei told the arterial network that this new revolutionary product can be used in hospitals or central laboratories. For hospitals, products must be approved by national regulatory authorities before they can be used. This takes 1-2 years; for central laboratories, eLB can now be used for scientific research services, or for specific populations and Volunteers provide testing services.
Source: Arterial Network
Arterial Blood Gas Collection Syringe
Arterial Blood Gas Collection Syringe,Arterial Blood Syringe,Syringe,arterial blood gas syringe,disposable syringe
Anesthesia Medical Co., Ltd. , https://www.medicaldiverse.com